Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Login/Register
EN FR

PrSymbicort® budesonide/formoterol fumarate dihydrate

Welcome to
SYMBICORT

A website for Canadian CREs and RTs
Download SYMBICORT TURBUHALER Action Plan Download Starting SYMBICORT Guide
SYMBICORT TURBUHALER: The #1 dispensed ICS/LABA1

SYMBICORT TURBUHALER:

The #1 dispensed
ICS/LABA1

The #1
dispensed
ICS/LABA1

Discover SYMBICORT® TURBUHALER®, a treatment for your patients with asthma or moderate to severe COPD

In Canada, SYMBICORT TURBUHALER is indicated for2

The treatment of asthma in patients 12 years and older with reversible obstructive airways disease.

In Canada, SYMBICORT 200 TURBUHALER and SYMBICORT FORTE TURBUHALER are indicated for2

The maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate.

The latest CTS guidelines are available to help you educate your patients

Read the CTS Summary Booklet for key takeaways from the latest CTS recommendations about using budesonide/formoterol therapy to treat your patients with mild and moderate asthma.

Learn more about SYMBICORT TURBUHALER and access resources
designed to help you support your patients below.

COPD: chronic obstructive pulmonary disease; CRE: certified respiratory educator; RT: respiratory therapist; CTS: Canadian Thoracic Society; ICS: inhaled corticosteroid; LABA: long-acting beta2-adrenergic agonist.

 

References:

  • Data on file. AstraZeneca Canada Inc. April 15, 2024.
  • Symbicort® Turbuhaler® Product Monograph. AstraZeneca Canada Inc. February 8, 2021.
Back to Top